Genflow Biosciences PLC Announces Result of AGM

NYSE - LSE

RBGPF	0.33%	61.5	$
BTI	-0.9%	62.2	$
RIO	-0.29%	93.47	$
CMSC	0.3%	21.995	$
BCE	-0.81%	22.735	$
AZN	0.49%	189.33	$
RELX	0.52%	31.505	$
NGG	0.54%	83.46	$
RYCEF	4%	18.75	$
BCC	-2.95%	78.7	$
JRI	0.08%	12.8	$
VOD	-1.61%	13.67	$
GSK	-0.36%	52.31	$
BP	1.13%	37.555	$
CMSD	0.07%	21.785	$

Genflow Biosciences PLC Announces Result of AGM

BOULEVARD 29.06.2026

LONDON, UK / ACCESS Newswire / June 29, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, is pleased to announce that all resolutions proposed at the Annual General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.

Text size:

Proxy Voting Results

Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Votes withheld
1. To receive and consider the Annual Report and Accounts for the year ended 31 December 2025 together with the Directors' Report and Auditors' Report thereon.	102,370,028	99.94%	56,893	0.06%	102,426,921	1,058
2. To approve the directors' remuneration report for the financial period ended 31 December 2025 set out in the audited accounts for the financial period ended 31 December 2025.	102,348,305	99.92%	78,616	0.08%	102,426,921	1,058
3. To re-appoint PKF Littlejohn LLP as auditors of the Company and to authorise the Directors of the Company to fix their remuneration.	102,370,094	99.94%	56,603	0.06%	102,426,697	1,282
4. To re-elect Gad Berdugo as a Director of the Company.	102,363,749	99.93%	64,006	0.07%	102,427,755	224
5. To re-elect Dr Eric Leire as a Director of the Company.	102,363,557	99.93%	64,198	0.07%	102,427,755	224
6. To re-elect Tamara Joseph as a Director of the Company.	102,363,557	99.93%	64,198	0.07%	102,427,755	224
7. To re-elect Dr Yassine Bendiabdallah as a Director of the Company.	102,363,459	99.70%	64,296	0.30%	102,427,755	224
8. To re-elect Guy-Charles Fanneau De La Horie as a Director of the Company.	102,363,459	99.70%	64,296	0.30%	102,427,755	224
9. To approve the adoption of the share option scheme (the "Scheme") by the Company.	101,237,554	98.86%	1,162,031	1.13%	102,399,585	28,394
10. To authorise the Directors of the Company to allot shares for the Scheme Options (up to 14.34%)	101,264,434	98.86%	1,162,321	1.14%	102,426,465	1,224
11. To authorise the Directors of the Company to allot shares (up to 33%)	101,264,724	98.86%	1,162,031	1.14%	102,426,755	1,224
Special Resolution	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Votes withheld
12. To disapply statutory pre-emption rights in respect of Resolution 10 (Scheme Options)	101,218,852	98.82%	1,208,127	1.18%	102,426,979	1,000
13. To disapply statutory pre-emption rights in respect of Resolution 11	101,191,458	98.79%	1,235,521	1.21%	102,426,979	1,000

Contacts
Genflow Biosciences	Harbor Access
Dr Eric Leire, CEO	Jonathan Paterson, Investor Relations
+32-477-495-881	+1 475 477 9401
	[email protected]

About Genflow
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments.

Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Genflow Biosciences PLC

View the original press release on ACCESS Newswire

A.Moore--AT

Arizona Tribune - Genflow Biosciences PLC Announces Result of AGM

Genflow Biosciences PLC Announces Result of AGM

Featured

Chavez-era housing complex in ruins after Venezuela quakes

Catholic traditionalists risk schism in Church

Venezuela search teams scramble as hope fades of finding quake survivors

Cape Verde, Africa's outlier in LGBTQ tolerance